Molecular Detection of *gyrA*, *parC* and *oprD* Mutation in *Pseudomonas aeruginosa* Isolates from a University Hospital of Isfahan, Iran during 2016

Hossein Fazeli ¹, Seyed Asghar Havaei ¹, Samaneh Saedi ², Ali Badamchi ³, Fateme Zahra Zamani ⁴, Hamid Solgi ²*

¹ Department of bacteriology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
² Department of Bacteriology and Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran.
³ Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Dental School, Isfahan University of Medical Sciences, Isfahan, Iran.

**ARTICLE INFO**

**Article type:** Original Article

**Article history:**
Received: 17 Dec 2016
Revised: 12 Feb 2017
Accepted: 20 Feb 2017
Published: 15 Apr 2017

**Keywords:** *gyrA*, *parC*, *oprD*, *P. aeruginosa*, Sequence.

**ABSTRACT**

**Background:** Excessive use of broad-spectrum antibiotics in hospitals has led to the emergence of highly resistant strains of *Pseudomonas aeruginosa*. The main mechanism of resistance of this bacterium to fluoroquinolones and carbapenems are the modification of type II topoisomerases (*DNA gyrase and topoisomerase IV*) and alterations in the OprD porin, respectively. The aim of this study was to examine for the occurrence of mutations related to fluoroquinolone resistance of *gyrA* and *parC* genes and mutational inactivation of *oprD* gene of clinical isolates using DNA sequencing technique.

**Methods:** A total of 60 *P. aeruginosa* isolates were collected from the hospitalized patients in the Intensive Care Units (ICUs) of Al-Zahra hospital located in Isfahan, Iran. The pattern of sensitivity to antibiotics was determined using CLSI disk diffusion and MIC methods. The assay was based on a DNA sequencing method using polymerase chain reaction (PCR) for amplification and sequencing of the selected genes.

**Results:** The results show that replacement of Ile for Thr-83 in *gyrA* was the only replacement, while other substitutions not observed. No mutations were found in *parC*. The most frequent amino acid alterations were E185Q, P186G, and V189T, found in five resistance isolates. However, nucleotide insertions and deletions mutations not observed.

**Conclusion:** Our study suggested that mutation of *gyrA* and *oprD* genes may play a minor role in fluoroquinolone and carbapenem resistance and other mechanisms may contribute to the fluoroquinolone and carbapenem resistance of *P. aeruginosa*. 

Introduction

*Pseudomonas aeruginosa* is an important pathogen of nosocomial infections, especially in the Intensive Care Units (ICUs) and is generally resistant to many antibiotics especially in ICUs. Multidrug-resistant (MDR) *P. aeruginosa* "resistance to at least 3 classes of antibiotics" are often isolated from nosocomial infections in ICUs (1-4) and emergence of resistant often seen in the ICUs. MDR *P. aeruginosa* infections are associated with the increased price of care, length of hospitalization and mortality (4, 5). Only a few antibiotics, such as carbapenem and fluoroquinolone, show potent bactericidal activity against MDR *P. aeruginosa* infections (6-9). Therefore, knowing the mechanisms of resistance and developing alternative therapies for these isolates is very important (1). *P. aeruginosa* acquires resistance to antibiotics through chromosomal mutations. These mutations include: mutations in the target genes encoding DNA gyrase (*gyrA*) and topoisomerase IV (*parC*) and mutations causing cell wall impermeability due to loss of *OprD*, a porin that forms narrow transmembrane channels. Resistance to imipenem and reduced susceptibility to meropenem are reported to be associated with loss of OprD porin (4). Mutations in the target genes that encode gyrA and parC are the main mechanisms of resistance to fluoroquinolones. Mutational studies have shown that gyrA mutations in codon 83 (Thr→Ile) and codon 87 (Asp→Tyr or Asp→Asn) have been associated with higher fluoroquinolone resistance. *parC* mutations in codon 80 (Ser→Leu), and codon 84 (Glu→Lys) are associated with elevated fluoroquinolone resistance. Multiple mutations in both gyrA and parC genes in codons 80, 83, 84, and 87 are linked to much more elevated resistance in *P. aeruginosa* (4, 10). The important known mechanisms of resistance to carbapenems in *P. aeruginosa* are inactivating mutations in OprD have been documented to confer resistance to imipenem and to a lesser extent to meropenem (3, 11, 12). The aim of this study is to determine the antimicrobial resistance rates and point mutations in oprD and gyrA genes of MDR *P. aeruginosa* strains isolated from the hospitalized patients in ICU of Al-Zahra hospital in Isfahan, Iran.

Material and method

Clinical Isolates

In this cross-sectional study, clinical isolates of *P. aeruginosa* were collected during August 2015 to April 2016 from hospitalized patients in ICU of the main hospital, Isfahan, Iran (Alzahra hospital). Specimens were cultured as described by others (13). The specimens taken from urinary tract (22), tracheal aspirate (20) blood (18) and other sites were cultured.

Identification of *P. aeruginosa* strains

Bacteria isolates from clinical specimens were identified according to Gram stain and biochemical tests such as growth at 42 °C, catalase, oxidase, pyocyanin production, citrate utilization, triple iron sugar utilization, oxidative-fermentative test with glucose, and methyl red-Voges Proskauer as described in standard bacteriological methods (10).

Antimicrobial susceptibility testing, Disk diffusion

Antimicrobial susceptibility tests were performed by the Kirby-Bauer disk diffusion method based as recommended by National Committee for CLSI, USA with a panel of anti-pseudomonal antimicrobials of standard strengths as follows: ceftazidime (30μg), piperacillin (100μg), piperacillin/-tazobactam (100μg), gentamicin (10μg), amikacin (30μg), imipenem (10μg), meropenem (10μg), ciprofloxacin (5μg), cefepim (30μg), aztreonam (30μg), levofloxacin (5μg) (MAST Co., UK). Control strains *P. aeruginosa* ATCC 27853 and *Escherichia coli* ATCC 25922 (14) were included in assays. Statistical analyses were performed using WHO net version 5.6.
**Determination of MIC**

The E-test was performed using Mueller-Hinton agar plates (diameter, 140 mm). The MIC of imipenem and ciprofloxacin was determined by the E-test method, according to the manufacturer’s instructions (Liofilchem, Italy). The MICs of the E-test were rounded up to the next most two-fold dilution for comparison of results with the reference method. Quality control was tested by *E. coli* ATCC 25922 (11).

**PCR amplification and DNA sequencing**

Chromosomal DNA was extracted using a DNA extraction kit (Sinaclon, Iran) according to the manufacturer’s instructions and were used as template for PCR reactions. PCR amplification of *gyrA*, *oprD* and *parC* genes was performed with whole-DNA extracts from 5 randomly selected FQ and carbapenem resistant clones by using the primers described in table 1. In each case, two independent PCR products were fully sequenced as described above, and the resulting sequences were compared with those of the reference strain PAO1. Multiple sequence aligned by PBIL (PôleBioinformatique Lyonnais) of *gyrA*, *oprD* and *parC* genes from PAO1 and clinical isolates (15, 16).

**Results**

**Antimicrobial susceptibility testing**

In our study the highest resistance ratio was found against meropenem (66.2%) and levofloxacin (66.2%), and the least resistance belonged to amikacin (50.8%) (Table 2). According to the standard breakpoints, our data revealed that 100% of isolates of *P. aeruginosa* had MICs ≥256 μg/ml and MICs ≥32 μg/ml to imipenem and ciprofloxacin, respectively.

**Comparison of disk diffusion method and E-test for imipenem and ciprofloxacin**

Using the disk diffusion method, 30 of 30 (100%) of the MDR *P. aeruginosa* isolates showed resistance to imipenem and ciprofloxacin. Also E-test using confirmed disk diffusion method revealed that 30 of 30 (100%) of the MDR *P. aeruginosa* isolates were resistant to imipenem and ciprofloxacin. The number of *P. aeruginosa* strains resistant to two drugs, imipenem and ciprofloxacin, were similar in both assays, the disk diffusion method and E-test.

**gyrA, oprD and parC mutations**

Five clinical isolates of *P. aeruginosa* were examined for the occurrence of mutations related to FQ and carbapenem resistance. To identify point mutations, sequences from clinical isolates were compared with those of wild-type *P. aeruginosa* PAO1. PCR analysis followed by sequencing showed the presence of the *gyrA* and *oprD* gene in clinical isolates (Table 3 and Table 4). The results showed that all of the clinical isolates had a single point mutation in *gyrA* gene. Since alterations in the OprD porin can cause imipenem resistance, four chosen clinical isolates were subjected to sequencing for *OprD* gene. No mutations were found in *parC*. Amino acid changes found among these carbapenem resistant *P. aeruginosa* strains are displayed in table 4.

**Discussion**

Fluoroquinolone and Carbapenem resistance mechanisms resulting from chromosomal mutations. The involvement of the classical mutational mechanisms in the fluoroquinolone and carbapenem resistance of the *P. aeruginosa* strains from the Iran hospitals has not investigated (5). Fluoroquinolone resistance in *P. aeruginosa* has been associated with substitutions in the gyrA subunit of DNA gyrase and in the parC subunit of
Table 1. Primers used in this study.

<table>
<thead>
<tr>
<th>Gene</th>
<th>primer name</th>
<th>sequence5´–3´</th>
<th>reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>gyrA</td>
<td>gyrA-F</td>
<td>AGTCCTATCTCACTACGCGAT</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>gyrA-R</td>
<td>AGTGCAGGTTTCTTCTTCCAG</td>
<td></td>
</tr>
<tr>
<td>oprD</td>
<td>oprD-F</td>
<td>TGCTGCTCGCAACTAATTTTC</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>oprD-R</td>
<td>GTAGGGCAAAGTGAAAGTG</td>
<td></td>
</tr>
<tr>
<td>parC</td>
<td>parC-F</td>
<td>CGAGCAGGCTATCTGAACTAT</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>parC-R</td>
<td>GAAGGACTTGGGATCGTCCGA</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Results of antibiotic susceptibility tests of isolated strains of *P. aeruginosa*.

<table>
<thead>
<tr>
<th>Antibacterial Class</th>
<th>Antibiotic</th>
<th>Sensitive no%</th>
<th>Intermediate no%</th>
<th>Resistant no%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinolones</td>
<td>Ciprofloxacin</td>
<td>26.6</td>
<td>5</td>
<td>68.3</td>
</tr>
<tr>
<td></td>
<td>Levofoxacin</td>
<td>25</td>
<td>1.6</td>
<td>70</td>
</tr>
<tr>
<td>Carbapenems</td>
<td>Meropenem</td>
<td>28.3</td>
<td>1.6</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>Imipenem</td>
<td>31.6</td>
<td>-</td>
<td>68.3</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>Gentamicin</td>
<td>30</td>
<td>3.3</td>
<td>66.6</td>
</tr>
<tr>
<td></td>
<td>Amikacin</td>
<td>43.3</td>
<td>1.6</td>
<td>55</td>
</tr>
<tr>
<td>Cephems</td>
<td>Cefepime</td>
<td>25</td>
<td>10</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>Ceftazidine</td>
<td>23.3</td>
<td>10</td>
<td>66.6</td>
</tr>
<tr>
<td>β-lactam+Inhibitor</td>
<td>Piperacillin/</td>
<td>28.3</td>
<td>15</td>
<td>56.6</td>
</tr>
<tr>
<td></td>
<td>Tazobactam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillins</td>
<td>Piperacillin</td>
<td>23.3</td>
<td>15</td>
<td>61.6</td>
</tr>
</tbody>
</table>

Table 3. Type of point mutations in gyrA and parC genes of *P. aeruginosa* strains

<table>
<thead>
<tr>
<th>GyrA</th>
<th>3,4,16,20,33</th>
<th>256</th>
<th>83</th>
<th>ACC→ATC</th>
<th>Thr→Ile</th>
</tr>
</thead>
<tbody>
<tr>
<td>ParC</td>
<td>3,4,16,20,33</td>
<td>256</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

MIC = minimum inhibitory concentration; CIP = ciprofloxacin
Table 4. oprD amino acid sequence alterations in carbapenem-resistant isolates.

<table>
<thead>
<tr>
<th>Strain no.</th>
<th>MIC µg/mL</th>
<th>Amino acid position and substitutions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IMP 103 115 170 185 186 189 202 210 230 240 262 276</td>
</tr>
<tr>
<td>PAO1</td>
<td>0.6</td>
<td>T    K    F    E    P    V    E    I    E    S    N</td>
</tr>
<tr>
<td>H1</td>
<td>32</td>
<td>Q    G    T    Q    A    K    T    T</td>
</tr>
<tr>
<td>H4</td>
<td>32</td>
<td>S    T    L    Q    G    T</td>
</tr>
<tr>
<td>H14</td>
<td>32</td>
<td>S    T    L    Q    G    T</td>
</tr>
<tr>
<td>H16</td>
<td>32</td>
<td>S    T    L    Q    G    T</td>
</tr>
<tr>
<td>H33</td>
<td>32</td>
<td>S    T    L    Q    G    T</td>
</tr>
</tbody>
</table>

MIC = minimum inhibitory concentration; IMP = imipenem

DNA topoisomerase IV (10, 17, 18). Mutations in oprD caused by nucleotide deletions, insertions and point mutations in the oprD structural gene have been found to be the main mechanisms leading to inactivation of OprD porin from P. aeruginosa (12). In this study sequences of QRDR of gyrA, parC and as well as oprD gene of carbapenem resistant P. aeruginosa strains were examined by PCR and sequencing (5). Our results showed that among the five fluoroquinolone resistant P. aeruginosa that were randomly selected, only one type mutation in the gyrA gene was detected in all isolates. The nucleic acid substitutions in gyrA that occurred in these codons changed the amino acid profile from Thr to Ile (ACC:ATC). Common mutations in fluoroquinolone-resistant strains occurred in codon 80 of the parC gene but, our results showed the absence of alterations in the parC gene (4). There are numerous reports of the correlation between gyrA mutations with or without additional alterations in QRDR of parC (4, 10, 15, 16, 19).

Multiple studies have evaluated the importance of oprD substitutions in clinical isolates of P. aeruginosa resistant to carbapenems. Mutations in oprD caused by nucleotide deletions, insertions and point mutations in the oprD structural gene have been found to be the major mechanisms leading to inactivation of OprD porin from P. aeruginosa (12).

Mutational inactivation of oprD is the main mechanism of carbapenem resistance in the absence of acquired carbapenemases (8). Since alterations in the OprD porin can cause carbapenem resistance, we sequenced the oprD gene for clinical strains. The most frequent causes of oprD mutational inactivation were point mutations leading to alterations the amino acid profile (5). These amino acid alterations were frequent in the P. aeruginosa strains tested in this study, whereas these alterations probably lead to carbapenem resistance. The most frequent amino acid alterations were E185Q, P186G, and V189T, found in five resistance isolates. This result was in accordance with previous reports on clinical isolates of P. aeruginosa. However, in our study unlike other studies, nucleotide insertions and deletions mutations not observed (3, 12, 20). In this
study, were found also a number of mutations in the third codon that did not affect the protein sequence which confirm other reports (21).

Conclusion

In conclusion, this study show that the primary mechanism of fluoroquinolone resistance in P. aeruginosa is mediated through target site substitutions, specifically a Thr-83 to Ile alteration in gyrA and as well as point mutations in the oprD structural gene that leading to change the amino acid profile that plays a crucial role in carbapenem resistance. However, we know that other molecular experiments such as quantitative reverse transcription PCR and SDS page analysis showing protein profiles are required to reach comprehensive and valuable results about the carbapenem resistant P. aeruginosa strains.

Acknowledgements

The authors acknowledge the Vice Chancellor for Research at Isfahan University of Medical Sciences for financial support of the research.

Ethical Considerations

The study was ethically approved by the Isfahan University of Medical Sciences Ethic Commission and written informed Consent was obtained from all participants.

Conflict of interest

The authors declare no conflicts of interest.

Financial disclosure

The authors declared no financial disclosures.

References

8. Lee JY, Ko KS. OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea. Int J


